SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:SynCore Biotechnology Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013432
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that utilizes and in-licenses technologies to develop new drugs. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05. Its SB01 drug is a new chemical entity (NCE), which is developed for treating solid tumors, head and neck cancer. SynCore provides SB02 for solid tumors; and SB04 for age-related macular degeneration. The company’s SB05 is a composition of cytostatic drug paclitaxel combined with neutral and positive lipids is being developed for breast cancer. Its marketed product SB03 is an ointment developed for the treatment of external genital warts. The company partners with other pharmaceutical companies, non-profit foundation and biotechnology company. It operates through its offices in I-Lan and Taipei, Taiwan. SynCore is headquartered in Yilan, Taiwan.

SynCore Biotechnology Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 10
Partnerships 11
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 11
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 12
Licensing Agreements 13
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 13
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Enters Into Licensing Agreement With Syncore Biotech For Veregen 15
Equity Offering 16
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 16
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 17
SynCore Biotech to Raise Funds through Public Offering of Shares 18
SynCore Biotech to Raise Funds through Rights Offering of Shares 19
SynCore Biotechnology Co Ltd – Key Competitors 20
SynCore Biotechnology Co Ltd – Key Employees 21
SynCore Biotechnology Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SynCore Biotechnology Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
SynCore Biotechnology Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 10
SynCore Biotech Enters into Co-Development Contract with Aju Pharm 11
National Taiwan University Hospital Forms Joint Venture with SynCore Biotech 12
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 13
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 14
MediGene Enters Into Licensing Agreement With Syncore Biotech For Veregen 15
SynCore Biotech to Raise USD8.7 Million in Rights Offering of Shares 16
SynCore Biotech to Raise USD1.1 Million in Public Offering of Shares 17
SynCore Biotech to Raise Funds through Public Offering of Shares 18
SynCore Biotech to Raise Funds through Rights Offering of Shares 19
SynCore Biotechnology Co Ltd, Key Competitors 20
SynCore Biotechnology Co Ltd, Key Employees 21
SynCore Biotechnology Co Ltd, Other Locations 22
SynCore Biotechnology Co Ltd, Joint Venture 22

★海外企業調査レポート[SynCore Biotechnology Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Quidel Corp (QDEL):企業の財務・戦略的SWOT分析
    Quidel Corp (QDEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mega Uranium Ltd (MGA):企業の財務・戦略的SWOT分析
    Mega Uranium Ltd (MGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Medeon Biodesign Inc (6499):医療機器:M&Aディール及び事業提携情報
    Summary Medeon Biodesign Inc (Medeon Biodesign) is a medical device company that develops patient-centered medical device products that address unmet medical needs. The company’s products include cardiovascular devices and equipment, devices for minimally invasive surgeries, laparoscopic device, hig …
  • PhoreMost Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary PhoreMost Ltd (PhoreMost) is a drug discovery company that develops drugs for the treatment of cancer. The company's lead drug discovery program is based on a novel target, which tackles the undruggable cancer gene KRAS that affects various types of cancer. It develops Site-Seeker, a platfor …
  • Premier Foods plc (PFD):企業の財務・戦略的SWOT分析
    Premier Foods plc (PFD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Midatech Pharma US Inc:医療機器:M&Aディール及び事業提携情報
    Summary Midatech Pharma US Inc (Midatech Pharma), formerly DARA BioSciences, Inc., is a pharmaceutical company which focuses on the development and commercialization of cancer treatment and supportive care products. It is a subsidiary of Midatech Pharma Plc. The company’s product portfolio includes …
  • Morinaga & Co., Ltd. (2201):企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Origin Enterprises PLC:企業のM&A・事業提携・投資動向
    Origin Enterprises PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Origin Enterprises PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Global Clean Energy Holdings Inc (GCEH):企業の戦略的SWOT分析
    Global Clean Energy Holdings Inc (GCEH) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Johnson Matthey Plc (JMAT):電力:M&Aディール及び事業提携情報
    Summary Johnson Matthey Plc (Johnson Matthey) is a specialty chemicals and sustainable technologies provider. It offers catalysts, fine chemicals, specialty chemical products and related technologies for various chemical processes and applications. It also undertakes the marketing, distribution, fab …
  • Voith Hydro Holding GmbH & Co KG:企業の戦略的SWOT分析
    Voith Hydro Holding GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Protagen AG-製薬・医療分野:企業M&A・提携分析
    Summary Protagen AG (Protagen) is a medical device company that develops molecular diagnostic and companion diagnostic test equipment. The company’s products include multilisa Ssc, multilisa SLE and multilisa RA. It provides products for autoimmune diseases such as rheumatoid arthritis, neuromyeliti …
  • ArcelorMittal:企業の戦略・SWOT・財務情報
    ArcelorMittal - Strategy, SWOT and Corporate Finance Report Summary ArcelorMittal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tullow Oil Plc (TLW):石油・ガス:M&Aディール及び事業提携情報
    Summary Tullow Oil Plc (Tullow) is an independent upstream oil and gas company. It explores for, develops and produces oil and natural gas in Africa and South America. The company has licenses, both onshore and offshore, across Africa, and offshore exploration licenses in Guyana, Suriname, Uruguay, …
  • ShotSpotter Inc (SSTI):企業の財務・戦略的SWOT分析
    ShotSpotter Inc (SSTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Athabasca Oil Corp (ATH):石油・ガス:M&Aディール及び事業提携情報
    Summary Athabasca Oil Corp (Athabasca) is an upstream energy company which focuses on exploration, development and production of bitumen, light oil and liquids-rich natural gas from oil sands and related assets. The company employs multi-stage fracturing and horizontal drilling technology from uncon …
  • Nido Petroleum Limited:石油・ガス:M&Aディール及び事業提携情報
    Summary Nido Petroleum Limited (Nido), a subsidiary of BCP Energy International Pte. Ltd, is an upstream energy company. It explores for, develops, and produces oil and gas. Nido holds working interests in exploration permits in the North West Palawan basin of the Philippines. The company operates t …
  • Elron Electronic Industries Ltd (ELRNF)-医療機器分野:企業M&A・提携分析
    Summary Elron Electronic Industries Ltd (Elron), a subsidiary of IDB Holding Corp Ltd is a holding company that offers medical devices and technology solutions. The company offers patient care systems for stroke care, microbiology, age-related macular degeneration, orthopedics, and heart diseases. I …
  • Sumitomo Heavy Industries Ltd (6302):企業の財務・戦略的SWOT分析
    Sumitomo Heavy Industries Ltd (6302) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Catholic Health Initiatives:製薬・医療:M&Aディール及び事業提携情報
    Summary Catholic Health Initiatives (CHI) is a health system comprising of non-profit and for profit corporations and other organizations including Catholic health care systems. It serves people through operations and facilities that span the continuum of care, comprising acute care hospitals; long- …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆